23 Jul, 2018 New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at PNS Annual Meeting
We presented new analyses from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the 2018 Peripheral Nerve Society (PNS) Annual Meeting, held July 22-25, 2018 in Baltimore, MD.
Gonzalez-Duarte et al. – “Changes in Neuropathy Stage in Patients with Hereditary Transthyretin-Mediated Amyloidosis Following Treatment with Patisiran, an Investigational RNAi Therapeutic: An Analysis from the Phase 3 APOLLO Study”
We believe the new data presented, which include results demonstrating overall health status improvements in patisiran-treated patients compared to placebo, underscore the potential clinical benefit of patisiran for patients with hATTR amyloidosis.